Bi-Specific MAbS Market Size, Emerging Trends, Market Opportunities, Key Players And Forecast To 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Bi-Specific MAbS Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $16.9 billion In 2028 At A CAGR Of 13.3% :

The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding and government initiatives.

The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population and an increase in the prevalence of chronic diseases. Major trends in the forecast period include focus on technological advancements, product innovation, focus on artificial intelligence, investment in targeted and combination therapy and strategic partnerships.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Bi-Specific MAbS Market Major Segments
The bi-specific mabs market covered in this report is segmented -

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users

Key Driver - Impact Of Increasing Cancer Prevalence On The Bi-Specific Mabs Market

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer related deaths in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=3390&type=smp

Prominent Trend - Strategic Collaborations And Partnerships Fuel Growth In The Bi-Specific Mabs Market

Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives, such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. A strategic collaboration is a cooperative partnership between two or more organizations to achieve common goals or objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical company and MacroGenics, a US-based biopharmaceutical company, entered into an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3 using MacroGenics' DART platform, along with two other bispecific research programs. The collaboration grants Gilead an exclusive option to license MGD024, which has the potential to treat various hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to minimize cytokine-release syndrome (CRS) and allow intermittent dosing, potentially leading to more patient-friendly treatment and improved clinical outcomes for individuals with AML and MDS .

Bi-Specific MAbS Market Players
Major companies operating in the bi-specific mabs market report are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Innovent Biologics, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, EpimAb Biotherapeutics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Bi-Specific MAbS Market Report Structure
3. Bi-Specific MAbS Market Trends And Strategies
4. Bi-Specific MAbS Market - Macro Economic Scenario
5. Bi-Specific MAbS Market Size And Growth
…..
27. Bi-Specific MAbS Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.